Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02424149 · ClinicalTrials.gov registry record · NA
Phenazopyridine for Confirmation of Ureteral Patency
A NA study of Cystoscopy, sponsored by Hartford Hospital.
- Completed
- Registry status
- NA
- Development phase
- 107
- Enrollment target
- 1
- Study location
NCT02424149 is a NA study of Cystoscopy that has completed, run by Hartford Hospital. The registered enrollment target is 107 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02424149, a NA study of Cystoscopy, has completed, sponsored by Hartford Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 107 participants
- Enrollment target
- 1
- Study location
Study Summary
In this prospective, randomized trial subjects will be randomized to receive phenazopyridine or no medication prior to pelvic reconstructive procedures that use cystoscopy to confirm ureteral patency intraoperatively.
Conditions Studied
Interventions
- DRUG Phenazopyridine
Study Locations (1)
Connecticut
- Hartford Hospital - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02424149
The ClinicalTrials.gov registry entry for NCT02424149 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hartford Hospital, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystoscopy appearing as the primary indexed condition, and to 1 intervention - of which Phenazopyridine is the first listed.
NCT02424149 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT02424149 about?
NCT02424149 is a clinical study titled "Phenazopyridine for Confirmation of Ureteral Patency". In this prospective, randomized trial subjects will be randomized to receive phenazopyridine or no medication prior to pelvic reconstructive procedures that use cystoscopy to confirm ureteral patency intraoperatively.
What is the current status of trial NCT02424149?
This trial is currently completed. It is a NA study. The enrollment target is 107 participants. The study started on 2015-04. Estimated completion is 2016-01.
What conditions does trial NCT02424149 study?
This clinical trial studies the following conditions: Cystoscopy.
What interventions are being tested in trial NCT02424149?
The interventions under investigation include: Phenazopyridine (DRUG).
Who is sponsoring clinical trial NCT02424149?
This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02424149 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystoscopy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.